Medtronic plc commenced the U.S. commercial launch of its MiniMed 780G automated insulin‑delivery system on December 2, 2025, after the FDA cleared the pairing of the MiniMed 780G with Abbott’s Instinct continuous glucose monitoring sensor earlier in the year. The launch means the system is now shipping to customers nationwide and can be ordered through Medtronic’s diabetes sales channels.
The MiniMed 780G automatically adjusts insulin delivery every five minutes based on real‑time glucose readings from the Instinct sensor, which offers a 15‑day wear time and a slim, discreet design. The integration delivers a seamless “smart dosing” ecosystem that improves time‑in‑range for people with type 1 diabetes, a key metric for clinical outcomes. The sensor’s 15‑day wear cycle reduces the need for daily sensor changes, while the MiniMed 780G’s advanced algorithm provides closed‑loop control that has been shown to increase time‑in‑range by up to 10 percentage points in clinical studies.
This launch is a cornerstone of Medtronic’s broader strategy to strengthen its Diabetes portfolio ahead of the planned spin‑off of the Diabetes business into a standalone company, MiniMed, by the end of 2026. By partnering with Abbott, Medtronic expands its sensor options beyond its own Guardian and Simplera lines, positioning the company to compete more aggressively against rivals such as Dexcom, Tandem, and Insulet. The move also signals Medtronic’s intent to offer a fully integrated, patient‑centric solution that can be tailored to individual preferences, a critical differentiator in a market that increasingly values choice and convenience.
Medtronic’s recent financial results underscore the importance of this launch. In the third quarter of fiscal 2025, the company reported revenue of $8.292 billion, up 4.1% on an organic basis, and a non‑GAAP diluted EPS of $1.39, beating analyst expectations by $0.04. The Diabetes segment generated $2.755 billion in revenue for FY2025, a 10.7% increase year‑over‑year, driven largely by higher sales of the MiniMed 780G and other insulin‑delivery devices. The launch is expected to accelerate this growth trajectory and support the projected revenue and margin targets for the standalone Diabetes company.
Que Dallara, EVP and President of Medtronic Diabetes, said the launch “expands a smart dosing ecosystem built for choice, so every person can find a solution that fits their life.” She added that the integration “provides a more convenient, integrated solution” that will help patients achieve better glycemic control. Dr. Steve Edelman, a type 1 diabetes advocate, noted that the pairing “has improved time in range for patients and offers a seamless experience,” highlighting the real‑world impact of the new system.
The launch strengthens Medtronic’s competitive position and supports the company’s long‑term strategy to deliver high‑margin, high‑growth products in the diabetes market. By offering a sensor‑agnostic, closed‑loop system, Medtronic can capture a larger share of the growing automated insulin‑delivery market, while the spin‑off will allow the Diabetes business to pursue its own innovation roadmap and capital allocation strategy, potentially unlocking additional value for shareholders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.